Neurocrine Biosciences, Inc. vs Regeneron Pharmaceuticals, Inc.
Side-by-side stock comparison based on AI earnings call analysis
Which stock has stronger management signals?
Regeneron Pharmaceuticals, Inc. currently has the stronger revenue growth signal.
Neurocrine Biosciences, Inc. and Regeneron Pharmaceuticals, Inc. show active capex signals based on earnings call analysis.
No strong fundraising signal is currently visible for either company.
| Metric | Neurocrine Biosciences, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Current Price | ₹156.39 | ₹621.52 |
| Market Cap | ₹15,725.01 Cr. | ₹65,159.56 Cr. |
| Industry | Biotechnology | Biotechnology |
| P/E Ratio | 23.958462 | 15.505009 |
| ROE (%) | — | — |
| Debt/Equity | — | — |
| Sales Growth 5Y (%) | — | — |
| Profit Growth 5Y (%) | — | — |
| Promoter Holding (%) | — | — |
| Revenue Rank | Rank 3 | Rank 2 |
| Margin Rank | Rank 3 | Rank 4 |
| Signal | — | — |
| Capex | Yes | Yes |
| Fundraise | No information | No information |